Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24507912 | 0.84 | AR (0.38) | AR | |
| SCHEMBL1970607 | 0.83 | CYP3A4 (0.48) | AR | |
| SCHEMBL11939085 | 0.79 | AR (0.34) | AR | |
| SCHEMBL11938969 | 0.76 | AR (0.35) | AR | |
| SCHEMBL17708515 | 0.76 | AR (0.50) | AR | |
| SCHEMBL21221254 | 0.75 | ALDH1A1 (0.43) | — | |
| SCHEMBL331207 | 0.74 | ALDH1A1 (0.41) | — | |
| SCHEMBL10712290 | 0.71 | VCAM1 (0.42) | AR | |
| SCHEMBL10713216 | 0.71 | CYP2A6 (0.39) | AR | |
| SCHEMBL3976812 | 0.71 | AR (0.51) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| EP-2819999-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Novartis AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013128421-A1 | SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
| US-7625923-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1722793-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Brystol-Myers Squibb Company (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087232-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197359-A1 | Bicyclic modulators of androgen receptor function | AR, ESRRA, NR5A1 | AR 1/4885 |
| US-20150299120-A1 | Spirohydantoin compounds and their use as selective androgen receptor modulators | NR5A1, AR, SRD5A1 | AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.